G. Gaspar - Concepedia

Author

G. Gaspar

Also Known As

D L Orjuela Zuluaga, G Gaspar, G Gaspar Alonso-Vega, G Pérez, G. GASPAR, G. Gaspar, G. Gaspar Alonso-Vega, G. Perez, G. Pérez, Gabriel A-V. Gaspar

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario de Getafe Hospital Universitario Príncipe de Asturias Hospital General Universitario Gregorio Marañón Fundación Seimc-Gesida Hospital Universitario La Paz

About

G. Gaspar is an author at Hospital Universitario de Getafe specializing in medicine, nephrology, and hospital medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	641
2	Public Health	3	3	527
3	Epidemiology	2	2	516
4	Global Health	1	1	418
5	Health Policy	1	1	11

G. Gaspar

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain Juan Berenguer, Pablo Ryan, Jesús Rodríguez‐Baño, Clinical Microbiology and Infection Long CovidGlobal HealthCovid-19 PandemicClinical EpidemiologyCovid-19 Epidemiology	2020	418
Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus Juan Berenguer, Elisa Boucourt Rodríguez, Pilar Miralles, Clinical Infectious Diseases	2012	159
Effect of Simultaneous Use of Highly Active Antiretroviral Therapy on Survival of HIV Patients With Tuberculosis María Velasco, Virgilio Castilla, José Sanz, JAIDS Journal of Acquired Immune Deficiency Syndromes	2009	113
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study Belén Gutiérrez‐Gutiérrez, María Dolores del Toro, Alberto M. Borobia, The Lancet Infectious Diseases Prognostic EvaluationDisease ProgressionMulticentre Cohort StudyClinical PhenotypesClinical Epidemiology	2021	98
All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice Juan Berenguer, Ángela Gil‐Martin, Inmaculada Jarrín, Hepatology	2018	72
Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection Juan Berenguer, Elena Rodríguez‐Castellano, Ana Carrero, Hepatology	2017	58
Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients Pedro Rodríguez Quesada, L López Esteban, Jimena Ramón García, International Journal of Clinical Pharmacy UrologyTenofovir-associated Renal ToxicityAntiviral TherapyChronic Viral InfectionHiv-infected Patients	2015	46
Renal Handling of Uric Acid in Normal Subjects by Means of the Pyrazinamide and Probenecid Tests Juan Puig, F Mateos Antón, A. Muñoz Sanz, The Nephron journals/Nephron journals Probenecid TestsRenal PathologyRenal FunctionRenal HandlingClinical Chemistry	1983	37
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus Juan Berenguer, J. Alvarez-Pellicer, Ana Carrero, Journal of Hepatology Viral RelapseViral PersistenceViral HepatitisImmunologyAntiviral Therapy	2013	27
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant Juan Berenguer, Inmaculada Jarrín, Leire Pérez‐Latorre, Open Forum Infectious Diseases	2018	27

Page 1